Head-to-head comparison of brain-derived pTau217 and total pTau217 for brain amyloid and tau pathology classification - PubMed
6 hours ago
- #Alzheimer's disease
- #Biomarkers
- #Tau pathology
- pTau217 is a promising blood-based biomarker for Alzheimer's disease (AD) detection.
- Brain-derived pTau217 (BD-pTau217) shows higher specificity for AD-related brain changes compared to total pTau217.
- BD-pTau217 has less interference from kidney dysfunction than total pTau217.
- BD-pTau217 correlates more strongly with amyloid-PET Centiloid values than total pTau217.
- BD-pTau217 outperforms total pTau217 in classifying amyloid-β (Aβ) pathology and identifying tau-positive individuals.
- The study suggests BD-pTau217 as a superior biomarker for early detection and staging of AD.